Elite Test Bank:
Pharmacology for Nurses
(Adams 7th Ed.) - 2026/2027
Standards
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The "Welcome to the Big Leagues" Hook
○ The "Panic Button" Cheat Sheet
● PART II: THE ELITE TEST BANK
○ Section 1: Foundational Syntax & Application (Questions 1–15)
■ Focus: Pharmacokinetics, Pharmacodynamics, and ISMP "Hard Deck"
Protocols.
○ Section 2: Professional Simulation (Questions 16–40)
■ Focus: 2026/2027 AHA, GOLD, ADA, and KDIGO Guidelines; Immediate
Clinical Actions.
○ Section 3: Grandmaster Synthesis (Questions 41–66)
■ Focus: Multi-System Toxicity, High-Stakes Antidotes, and Hemodynamic
Crises.
PART I: THE PRIMER
Mastering the 2026/2027 advanced pharmacological landscape separates algorithmic
technicians from autonomous clinical architects. Your professional survival and patient
outcomes depend entirely on synthesizing phenotype-driven data, not memorizing obsolete
legacy protocols.
The "Panic Button" Cheat Sheet:
● AHA 2026 HTN Threshold: Universal target <130/80 mmHg. Initiate pharmacotherapy in
Stage 1 ONLY if the PREVENT calculator 10-year risk is ≥7.5%.
● GOLD 2026 COPD Paradigm: A single moderate exacerbation mandates treatment
escalation; blood eosinophils ≥300 cells/µL dictate immediate biologic intervention
(Dupilumab).
● ADA 2026 AID Standard: Automated Insulin Delivery (AID) systems are the absolute
preferred baseline for insulin-requiring diabetes, stripping away legacy "sliding scale"
delays.
● KDIGO 2026 CKD Mandate: Non-steroidal MRAs (Finerenone) are pillar therapy for
diabetic CKD, initiated solely if baseline potassium is ≤4.8 mmol/L.
● The Delegation Hard Deck: The registered nurse must NEVER delegate clinical
, judgment, initial assessment, or outcome evaluation.
PART II: THE ELITE TEST BANK
Section 1: Foundational Syntax & Application
Q1: A practitioner is reviewing the pharmacokinetic profile of an orally administered
narrow-therapeutic-index drug. The drug is highly susceptible to the hepatic first-pass effect.
Which pharmacokinetic outcome is MOST LIKELY expected if the client develops severe
hepatic cirrhosis? A) Increased drug clearance leading to subtherapeutic serum trough levels.
B) Decreased systemic bioavailability due to impaired gastrointestinal absorption. C) Profoundly
elevated systemic drug concentrations leading to fatal toxicity. D) Accelerated renal excretion
secondary to hepatorenal compensatory mechanisms.
● The Answer: C (Profoundly elevated systemic drug concentrations leading to fatal
toxicity.)
● Distractor Analysis:
○ A is incorrect: Cirrhosis impairs enzymatic clearance; it does not increase it.
○ B is incorrect: The first-pass effect destroys drug before it reaches systemic
circulation. A failing liver destroys less drug, meaning more is absorbed
systemically.
○ D is incorrect: Hepatorenal syndrome diminishes renal clearance; it does not
accelerate it.
The Mentor's Analysis: The liver acts as the primary gatekeeper for oral medications. The
first-pass effect metabolizes a massive fraction of the drug before it ever hits the systemic
circulation. When this gatekeeper fails (cirrhosis), the gates are left wide open, allowing a lethal
surge of the active drug into the bloodstream. Professional Intuition: Always anticipate cutting
the oral dose of high-first-pass drugs to fractions in hepatically impaired clients.
Q2: A client is prescribed a non-selective beta-adrenergic antagonist for essential hypertension.
The client has a documented medical history of GOLD Group A Chronic Obstructive Pulmonary
Disease (COPD). Which physiological response must the practitioner IMMEDIATELY
anticipate? A) Profound systemic vasodilation and orthostatic collapse. B) Acute
bronchoconstriction and severe respiratory distress. C) Reflex tachycardia secondary to
baroreceptor stimulation. D) Enhanced bronchodilation due to beta-2 receptor agonism.
● The Answer: B (Acute bronchoconstriction and severe respiratory distress.)
● Distractor Analysis:
○ A is incorrect: Alpha-1 blockade causes vasodilation; beta-blockers primarily reduce
cardiac output.
○ C is incorrect: Beta-blockers prevent tachycardia; they do not cause it.
○ D is incorrect: Non-selective beta-blockers antagonize (block) beta-2 receptors,
inducing bronchospasm, not bronchodilation.
The Mentor's Analysis: The autonomic nervous system is a seesaw. Non-selective
beta-blockers hit both Beta-1 (heart) and Beta-2 (lungs). Blocking Beta-2 strips away the
sympathetic nervous system's ability to keep airways open, dropping the client into an asthmatic
or COPD crisis. Professional Intuition: Never prescribe a non-selective beta-blocker to a
pulmonary client; demand cardioselective agents.
Q3: You are administering an emergency dose of intravenous naloxone to an unresponsive
client with pinpoint pupils and a respiratory rate of 4 breaths/minute. In the context of
, pharmacodynamics, how does this medication PRIMARILY reverse the crisis? A) It permanently
destroys the circulating opioid molecules in the plasma. B) It acts as a powerful central nervous
system stimulant, overriding the depression. C) It functions as a competitive antagonist,
physically displacing the opioid from the Mu (μ) receptors. D) It acts as an agonist at the GABA
receptors, restoring the respiratory drive.
● The Answer: C (It functions as a competitive antagonist, physically displacing the opioid
from the Mu (μ) receptors.)
● Distractor Analysis:
○ A is incorrect: Naloxone does not metabolize or destroy opioids; it only blocks their
binding.
○ B is incorrect: Naloxone has zero stimulant properties; it is purely a blocker.
○ D is incorrect: Naloxone works on opioid receptors, not GABA receptors (which are
targeted by benzodiazepines).
The Mentor's Analysis: Antagonists have affinity but no intrinsic activity. Naloxone is a
molecular bully. It shoves the opioid off the Mu receptor but does not activate the receptor itself.
Once the opioid is displaced, the respiratory drive immediately reboots. Professional Intuition:
Antagonists don't fix the problem by adding energy; they fix it by removing the suppressor.
Q4: A client taking a narrow-therapeutic-index medication is prescribed a new macrolide
antibiotic that is a known, potent cytochrome P450 (CYP3A4) enzyme inhibitor. What is the
MOST CRITICAL pharmacokinetic consequence of this drug-drug interaction? A) The
narrow-therapeutic drug will be metabolized too rapidly, causing treatment failure. B) The
narrow-therapeutic drug will accumulate in the plasma, leading to drug toxicity. C) The antibiotic
will bind to the target receptors, rendering the primary drug inert. D) The antibiotic will prevent
gastrointestinal absorption of the primary drug.
● The Answer: B (The narrow-therapeutic drug will accumulate in the plasma, leading to
drug toxicity.)
● Distractor Analysis:
○ A is incorrect: This describes the action of a CYP450 inducer, not an inhibitor.
○ C is incorrect: Enzyme inhibition relates to metabolism in the liver, not competitive
receptor binding at the tissue level.
○ D is incorrect: This describes an absorption phase interaction, not hepatic
metabolism.
The Mentor's Analysis: CYP450 enzymes are the liver's chemical incinerators. An "inhibitor"
shuts down the incinerator. If the incinerator is off, whatever drug is waiting to be processed
simply backs up into the bloodstream, creating massive, toxic spikes. Professional Intuition:
Enzyme Inhibitor = Toxicity Risk. Enzyme Inducer = Subtherapeutic Risk.
Q5: An advanced practitioner is calculating a pediatric drug dosage. The child weighs 22 kg.
The standard adult dose for the medication is 500 mg. Utilizing Clark’s Rule, what is the
SAFEST APPROXIMATE dosage for this client? A) 73 mg B) 161 mg C) 300 mg D) 450 mg
● The Answer: B (161 mg)
● Distractor Analysis:
○ A is incorrect: This represents a critical math error failing to convert kg to lbs before
dividing.
○ C is incorrect: This dosage is dangerously high for a child of this weight.
○ D is incorrect: This approaches an adult dose and will cause severe toxicity.
The Mentor's Analysis: Clark's rule is a foundational pediatric check, defined as: (Child's
weight in lbs / 150) x Adult Dose. First, convert 22 kg to pounds (22 x 2.2 = 48.4 lbs). Formula:
(48.) x 500 mg = 161.33 mg. Professional Intuition: Always convert to pounds before
Pharmacology for Nurses
(Adams 7th Ed.) - 2026/2027
Standards
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The "Welcome to the Big Leagues" Hook
○ The "Panic Button" Cheat Sheet
● PART II: THE ELITE TEST BANK
○ Section 1: Foundational Syntax & Application (Questions 1–15)
■ Focus: Pharmacokinetics, Pharmacodynamics, and ISMP "Hard Deck"
Protocols.
○ Section 2: Professional Simulation (Questions 16–40)
■ Focus: 2026/2027 AHA, GOLD, ADA, and KDIGO Guidelines; Immediate
Clinical Actions.
○ Section 3: Grandmaster Synthesis (Questions 41–66)
■ Focus: Multi-System Toxicity, High-Stakes Antidotes, and Hemodynamic
Crises.
PART I: THE PRIMER
Mastering the 2026/2027 advanced pharmacological landscape separates algorithmic
technicians from autonomous clinical architects. Your professional survival and patient
outcomes depend entirely on synthesizing phenotype-driven data, not memorizing obsolete
legacy protocols.
The "Panic Button" Cheat Sheet:
● AHA 2026 HTN Threshold: Universal target <130/80 mmHg. Initiate pharmacotherapy in
Stage 1 ONLY if the PREVENT calculator 10-year risk is ≥7.5%.
● GOLD 2026 COPD Paradigm: A single moderate exacerbation mandates treatment
escalation; blood eosinophils ≥300 cells/µL dictate immediate biologic intervention
(Dupilumab).
● ADA 2026 AID Standard: Automated Insulin Delivery (AID) systems are the absolute
preferred baseline for insulin-requiring diabetes, stripping away legacy "sliding scale"
delays.
● KDIGO 2026 CKD Mandate: Non-steroidal MRAs (Finerenone) are pillar therapy for
diabetic CKD, initiated solely if baseline potassium is ≤4.8 mmol/L.
● The Delegation Hard Deck: The registered nurse must NEVER delegate clinical
, judgment, initial assessment, or outcome evaluation.
PART II: THE ELITE TEST BANK
Section 1: Foundational Syntax & Application
Q1: A practitioner is reviewing the pharmacokinetic profile of an orally administered
narrow-therapeutic-index drug. The drug is highly susceptible to the hepatic first-pass effect.
Which pharmacokinetic outcome is MOST LIKELY expected if the client develops severe
hepatic cirrhosis? A) Increased drug clearance leading to subtherapeutic serum trough levels.
B) Decreased systemic bioavailability due to impaired gastrointestinal absorption. C) Profoundly
elevated systemic drug concentrations leading to fatal toxicity. D) Accelerated renal excretion
secondary to hepatorenal compensatory mechanisms.
● The Answer: C (Profoundly elevated systemic drug concentrations leading to fatal
toxicity.)
● Distractor Analysis:
○ A is incorrect: Cirrhosis impairs enzymatic clearance; it does not increase it.
○ B is incorrect: The first-pass effect destroys drug before it reaches systemic
circulation. A failing liver destroys less drug, meaning more is absorbed
systemically.
○ D is incorrect: Hepatorenal syndrome diminishes renal clearance; it does not
accelerate it.
The Mentor's Analysis: The liver acts as the primary gatekeeper for oral medications. The
first-pass effect metabolizes a massive fraction of the drug before it ever hits the systemic
circulation. When this gatekeeper fails (cirrhosis), the gates are left wide open, allowing a lethal
surge of the active drug into the bloodstream. Professional Intuition: Always anticipate cutting
the oral dose of high-first-pass drugs to fractions in hepatically impaired clients.
Q2: A client is prescribed a non-selective beta-adrenergic antagonist for essential hypertension.
The client has a documented medical history of GOLD Group A Chronic Obstructive Pulmonary
Disease (COPD). Which physiological response must the practitioner IMMEDIATELY
anticipate? A) Profound systemic vasodilation and orthostatic collapse. B) Acute
bronchoconstriction and severe respiratory distress. C) Reflex tachycardia secondary to
baroreceptor stimulation. D) Enhanced bronchodilation due to beta-2 receptor agonism.
● The Answer: B (Acute bronchoconstriction and severe respiratory distress.)
● Distractor Analysis:
○ A is incorrect: Alpha-1 blockade causes vasodilation; beta-blockers primarily reduce
cardiac output.
○ C is incorrect: Beta-blockers prevent tachycardia; they do not cause it.
○ D is incorrect: Non-selective beta-blockers antagonize (block) beta-2 receptors,
inducing bronchospasm, not bronchodilation.
The Mentor's Analysis: The autonomic nervous system is a seesaw. Non-selective
beta-blockers hit both Beta-1 (heart) and Beta-2 (lungs). Blocking Beta-2 strips away the
sympathetic nervous system's ability to keep airways open, dropping the client into an asthmatic
or COPD crisis. Professional Intuition: Never prescribe a non-selective beta-blocker to a
pulmonary client; demand cardioselective agents.
Q3: You are administering an emergency dose of intravenous naloxone to an unresponsive
client with pinpoint pupils and a respiratory rate of 4 breaths/minute. In the context of
, pharmacodynamics, how does this medication PRIMARILY reverse the crisis? A) It permanently
destroys the circulating opioid molecules in the plasma. B) It acts as a powerful central nervous
system stimulant, overriding the depression. C) It functions as a competitive antagonist,
physically displacing the opioid from the Mu (μ) receptors. D) It acts as an agonist at the GABA
receptors, restoring the respiratory drive.
● The Answer: C (It functions as a competitive antagonist, physically displacing the opioid
from the Mu (μ) receptors.)
● Distractor Analysis:
○ A is incorrect: Naloxone does not metabolize or destroy opioids; it only blocks their
binding.
○ B is incorrect: Naloxone has zero stimulant properties; it is purely a blocker.
○ D is incorrect: Naloxone works on opioid receptors, not GABA receptors (which are
targeted by benzodiazepines).
The Mentor's Analysis: Antagonists have affinity but no intrinsic activity. Naloxone is a
molecular bully. It shoves the opioid off the Mu receptor but does not activate the receptor itself.
Once the opioid is displaced, the respiratory drive immediately reboots. Professional Intuition:
Antagonists don't fix the problem by adding energy; they fix it by removing the suppressor.
Q4: A client taking a narrow-therapeutic-index medication is prescribed a new macrolide
antibiotic that is a known, potent cytochrome P450 (CYP3A4) enzyme inhibitor. What is the
MOST CRITICAL pharmacokinetic consequence of this drug-drug interaction? A) The
narrow-therapeutic drug will be metabolized too rapidly, causing treatment failure. B) The
narrow-therapeutic drug will accumulate in the plasma, leading to drug toxicity. C) The antibiotic
will bind to the target receptors, rendering the primary drug inert. D) The antibiotic will prevent
gastrointestinal absorption of the primary drug.
● The Answer: B (The narrow-therapeutic drug will accumulate in the plasma, leading to
drug toxicity.)
● Distractor Analysis:
○ A is incorrect: This describes the action of a CYP450 inducer, not an inhibitor.
○ C is incorrect: Enzyme inhibition relates to metabolism in the liver, not competitive
receptor binding at the tissue level.
○ D is incorrect: This describes an absorption phase interaction, not hepatic
metabolism.
The Mentor's Analysis: CYP450 enzymes are the liver's chemical incinerators. An "inhibitor"
shuts down the incinerator. If the incinerator is off, whatever drug is waiting to be processed
simply backs up into the bloodstream, creating massive, toxic spikes. Professional Intuition:
Enzyme Inhibitor = Toxicity Risk. Enzyme Inducer = Subtherapeutic Risk.
Q5: An advanced practitioner is calculating a pediatric drug dosage. The child weighs 22 kg.
The standard adult dose for the medication is 500 mg. Utilizing Clark’s Rule, what is the
SAFEST APPROXIMATE dosage for this client? A) 73 mg B) 161 mg C) 300 mg D) 450 mg
● The Answer: B (161 mg)
● Distractor Analysis:
○ A is incorrect: This represents a critical math error failing to convert kg to lbs before
dividing.
○ C is incorrect: This dosage is dangerously high for a child of this weight.
○ D is incorrect: This approaches an adult dose and will cause severe toxicity.
The Mentor's Analysis: Clark's rule is a foundational pediatric check, defined as: (Child's
weight in lbs / 150) x Adult Dose. First, convert 22 kg to pounds (22 x 2.2 = 48.4 lbs). Formula:
(48.) x 500 mg = 161.33 mg. Professional Intuition: Always convert to pounds before
